Theraclion

Strong Commercial Progress in the First Half of 2018 - Seite 2

K€		2018		2017		% vs 2017
Echopulses sales3		653		656		+0%
Echopulse rent		72		24		+202%
Consumables sales (a)		70		46		+54%
Service sales (b)		67		28		+142%
Sales Theraclion SA		862		753		+15%
Inc External Sales		680		549		+24%
Inc Sales to Theraclion SA branches		183		204		-11%
Externales Sales from branches		220		11		+1 962%
External sales Theraclion SA + branches		899		559		+61%
(a)+(b) Recurring sales		137		73		+87%

Growth in the number of treatments: + 89%

The total number of treatments increased by 89% in the first half.

The number of treatments in clinical routine (that is to say the treatments carried out outside a clinical study sponsored by Theraclion) is increasing by 68%: several reference sites in Germany, Spain and Hong Kong have switched over towards echotherapy as an effective and elegant method of treatment. The technique is also for them an important marketing differentiator.

The strong growth of treatments in sponsored studies is due to the completion of a study on the treatment of varicose veins in Austria and the acceleration of recruitment in the multicenter trial in the United States on the treatment of fibroadenoma, last step before accession to this gigantic market.